Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 1, 2013, Pages 6-17

  Natarajan, Viswanathan ^a,b   Dudek, Steven M ^a   Jacobson, Jeffrey R ^a   Moreno Vinasco, Liliana ^a   Huang, Long Shuang ^a   Abassi, Taimur ^a,b   Mathew, Biji ^a,b   Zhao, Yutong ^c   Wang, Lichun ^a,b   Bittman, Robert ^d   Weichselbaum, Ralph ^e   Berdyshev, Evgeny ^a,b   Garcia, Joe G N ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

S1P lyase; S1P receptors; Sepsis; Sphingolipids; Sphingosine kinase

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; FINGOLIMOD; FINGOLIMOD PHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LYASE; PHOSPHATASE; SIMVASTATIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; SYNTHETASE; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; AIRWAY OBSTRUCTION; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BLOOD VESSEL PERMEABILITY; BRADYCARDIA; CARDIOTOXICITY; CELL PERMEABILIZATION; CELL PROTECTION; CHEMOTAXIS; ENDOTHELIUM CELL; ENZYME INHIBITION; EXTRACELLULAR SPACE; HUMAN; IONIZING RADIATION; LEUKOCYTE ACTIVATION; LIPID METABOLISM; LUNG EDEMA; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MAMMAL CELL; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PNEUMONIA; PROTEIN EXPRESSION; RADIATION INJURY; REGULATORY MECHANISM; RESPIRATORY TRACT ALLERGY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; HUMANS; LUNG; LYSOPHOSPHOLIPIDS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PNEUMONIA; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SEPSIS; SPHINGOSINE; TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS); TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883176854     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0411TR     Document Type: Review

References (110)

1. Goss CH, Brower RG, Hudson LD, Rubenfeld GD. Incidence of acute lung injury in the United States. Crit Care Med 2003;31:1607-1611.
2. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr., Hoffman E, Hubmayr RD, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003;167:1027-1035.
3. Wynn Ta. Integrating mechanisms in pulmonary fibrosis. J Exp Med 2011;208:1339-1350.
4. Merrill AH, Schmelz E-M, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley KA, Wang E. Sphingolipids -the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997;142:208-225.
5. Uhlig S. Gulbins: sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-1114.
6. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis 2011;5:325-344.
7. Patwardhan GA, Liu YY. Sphingolipids and expression regulation of genes in cancer. Prog Lipid Res 2011;50:104-114.
8. Ratajczak MZ, Kim C,Wu W, Shin DM, Bryndza E, Kucia M, Ratajczak J. The role of innate immunity in trafficking of hematopoietic stem cells: an emerging link between activation of complement cascade and chemotactic gradients of bioactive sphingolipids. Adv Exp Med Biol 2012;946:37-54.
9. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011;121:4222-4230.
10. Gangoiti P, Camacho L, Arana L, Ouro A, Granado MH, Brizuela L, Casas J, Fabrias G, Abad JL, Delgado A, et al. Control of metabolism and signaling of simple bioactive sphingolipids: implications in disease. Prog Lipid Res 2010;49:316-334.
11. Mathew B, Jacobson JR, Berdyshev EV, Huang Y, Sun X, Zhao Y, Gerhold LM, Siegler J, Evanovski C, Wang T, et al. Critical role of sphingolipid pathway components in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogues. FASEB J 2011;25:3388-3400.
12. Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 2002;277:25843-25846.
13. Sugiura M, Kono K, Liu H, Shimizugawa T, Minekura H, Spiegel S, Kohama T. Ceramide kinase, a novel lipid kinase: molecular cloning and functional characterization. J Biol Chem 2002;277:23294-23300.
14. Canals D, Perry DM, Jenkins RW, Hannun YA. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 2011;163:694-712.
15. Piston SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011;36:97-107.
16. Ogawa C, Kihara A, Gokoh M, Igarashi Y. Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2. J Biol Chem 2003;278:1268-1272.
17. Brindley DN, Pilquil C. Lipid phosphate phosphatases and signaling. J Lipid Res 2009;50:S225-S230.
18. Zhao Y, Usatyuk PV, Gorshkova I, He D, Watkins T, Garcia JGN, Saatian B, Brindley DN, Bittman R, Berdyshev EV, et al. Regulation of intracellular generation of sphingosine-1-phosphate by lipid phosphate phosphatase-1 and sphingosine kinase 1 in human lung endothelial cells. J Biol Chem 2007;282:14165-14177.
19. Bandhuvula P, Saba JD. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol Med 2007;13:210-217.
20. Berdyshev EV, Gorshkova I, Usatyuk P, Kalari S, Zhao Y, Pyne NJ, Pyne S, Sabbadini RA, Garcia JGN, Natarajan V. Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: role of sphingosine kinase 1 and S1P lyase. PLoS ONE 2011;6:e16571.
21. Kariya Y, Kihara A, Ikeda M, Kikuchi F, Nakamura S, Hashimoto S, Choi CH, Lee YM, Igarashi Y. Products by the sphingosine kinase/ sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis. Genes Cells 2005;10:605-615.
22. Perrotta C, Clementi E. Biological roles of acid and neutral sphingomyelinases and their regulation by nitric oxide. Physiology (Bethesda) 2010;25:64-71.
23. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268:15523-15530.
24. Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995;270:22689- 22692.
25. Yatomi Y. Plasma sphingosine-1-phosphate metabolism and analysis. Biochim Biophys Acta 2008;1780:606-611.
26. Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202-1209.
27. Tani M, Sano T, Ito M, Igarashi Y. Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res 2005;46:2458-2467.
28. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008;102: 669-676.
29. Chung T, Crilly KS, Anderson WH, Mukherjee JJ, Kiss Z. ATPdependent choline phosphate-induced mitogenesis in fibroblasts involves activation of pp70 S6 kinase and phosphatidylinositol 39-kinase through an extracellular site: synergistic mitogenic effects of choline phosphate and sphingosine 1-phosphate. J Biol Chem 1997; 272:3064-3072.
30. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000;349:385-402.
31. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 2009;77:39-45.
32. Gimbrone MA Jr., Aster RH, Cotran RS, Corkerry J, Jandl JH, Folkman J. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 1969;222:33-36.
33. Schaphorst KL, Chiang E, Jacobs KN, Zaiman A, Natarajan V, Wigley F, Garcia JG. Role of sphingosine 1-phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 2003;285:L258-L267.
34. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689-701.
35. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004;170:987-993.
36. Okazaki M, Kreisel F, Richardson SB, Kreisel D, Krupnick AS, Patterson GA, Gelman AE. Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant 2007;7:751-758.
37. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiazova T, Sammani S, Lu X, Sun C, Harbeck M, Roe M, et al. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009;331:54-64.
38. Usatyuk PV, He D, Bindokas V, Berdyshev EV, Garcia JGN, Natarajan V. Photolysis of intracellular caged sphingosine-1-phosphate causes G-protein dependent and independent activation of cell signaling pathways in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2011;300:L840-L850.
39. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004;169:1245-1251.
40. Jacobson JR, Garcia JG. Novel therapies for microvascular permeability in sepsis. Curr Drug Targets 2007;8:509-514.
41. Ugolev Y, Berdichevsky Y, Weinbaum C, Edgar P. Dissociation of Rac1(GDP)oRhoGDI complexes by the cooperative action of anionic liposomes containing phosphatidylinositol 3,4,5-trisphosphate, Rac guanine nucleotide exchange factor, and GTP. J Biol Chem 2008;283:22257-22271.
42. Chae YC, Kim JH, Kim KL, Kim HW, Lee HY, Heo WD, Meyer T, Suh P-G, Ryu SH. Phospholipase D activity regulates integrinmediated cell spreading and migration by inducing GTP-Rac translocation to the plasma membrane. Mol Biol Cell 2008;19:3111-3123.
43. Van Veldhoven PP. Sphingosine-1-phosphate lyase. Methods Enzymol 2000;311:244-254.
44. Nakanaga K, Hama K, Aoki J. Autotaxin: an LPA producing enzyme with diverse functions. J Biochem 2010;148:13-24.
45. Zemann B, Urtz N, Reuschel R, Mechtcheriakova D, Bornancin F, Badegruber R, Baumruker T, Billich A. Normal neutrophil functions in sphingosine kinase Type 1 and 2 knockout mice. Immunol Lett 2007;109:56-63.
46. Vlasenko LP, Melendez AJ. A critical role for sphingosine kinase in anaphylatoxin-induced neutropenia, peritonitis, and cytokine production in vivo. J Immunol 2005;174:6456-6461.
47. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, Mandala S, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004;279:52487-52492.
48. Wadgaonkar R, Patel V, Grinkina N, Romano C, Liu J, Zhao Y, Sammani S, Garcia JGN, Natarajan V. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol 2009;296:L603-L613.
49. Puneet P, Yap CT, Wong L, Lam Y, Koh DR,Moochhala S, Pfeilschifter J, Huwiler A,Melendez AJ. SphK1 regulates pro-inflammatory responses associated with endotoxin and polymicrobial sepsis. Science 2010; 328:1290-1294.
50. Prakash H, Luth A, Grinkina N, Holzer D, Wadgaonkar R, Gonzalez AP, Anes E, Kleuser B. Sphingosine kinase-1 (SphK-1) regulates Mycobacterium smegmatis infection in macrophages. PLoS ONE 2010;5:e10657.
51. Bachmaier K, Guzman E, Kawamura T, Gao X, Malik AB. Sphingosine kinase 1 mediation of expression of the anaphylatoxin receptor C5L2 dampens the inflammatory response to endotoxin. PLoS ONE 2012;7:e30742.
52. Gorshkova I, Zhou T, Mathew B, Jacobson JR, Takekoshi D, Bhattacharya P, Smith B, Aydogan B, Weichselbaum RR, Natarajan V, et al. Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression. J Lipid Res 2011;53:1553-1568.
53. Mathew B, Huang Y, Jacobson JR, Berdyshev E, Gerhold LM, Wang T, Moreno-Vinasco L, Lang G, Zhao Y, Chen CT, et al. Simvastatin attenuates radiation-induced murine lung injury and dysregulated lung gene expression. Am J Respir Cell Mol Biol 2011;44:415-422.
54. Schmahl J, Raymond CS, Soriano P. PDGF signaling specificity is mediated through multiple immediate early genes. Nat Genet 2007; 39:52-60.
55. Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, Remaley AT, Saba JD, Proia RL. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 2010;285:10880-10889.
56. Allende ML, Bektas M, Lee BG, Bonifacino E, Kang J, Tuymetova G, Chen W, Saba JD, Proia RL. Sphingosine 1-phosphate deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 2011;286:7348-7358.
57. Oravecz T, Donoviel MS, Anderson SJ, Carson K, Sun W, Swaffield J, Liu Q, Kimball SD, Piggott JR, Zambrowicz BP, et al. Genetic and chemical inhibition of sphingosine 1-phosphate lyase results in peripheral lymphopenia and alleviates disease development in animal models of inflammation and autoimmunity [abstract]. Blood 2007; 110:2292.
58. Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, Anderson SJ, Sun W, Swaffield J, Oravecz T. Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS ONE 2009; 4:e4112.
59. Zhao Y, Gorshkova IA, Berdyshev E, Ma W, He D, Su Y, Usatyuk PV, Pendyala S, Fu P, Oskouian B, et al. Protection of LPS-induced murine acute lung injury and inflammation by sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol Biol 2012;45:426-435.
60. Kano-Sueoka T, Cohen DM, Yamaizumi Z, Nishimura S, Mori M, Fujiki H. Phosphoethanolamine as a growth factor of mammary carcinoma cell line of rat. Proc Natl Acad Sci USA 1979;76:5741-5744.
61. Kumar A, Byun H-S, Bittman R, Saba JD. The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell Signal 2011;23: 1144-1152.
62. Upadhyaya P, Kumar A, Byun H-S, Bittman R, Saba JD. The sphingolipid degradation product trans-2-hexadecenal forms adducts with DNA. Biochem Biophys Res Commun 2012;424:18-21.
63. Hailemariam TK, Huan C, Li J, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo M-S, Cao G, Wadgaonkar R, et al. Sphingomyelin synthase 2 deficiency attenuates NF-kB activation. Arterioscler Thromb Vasc Biol 2008;28:1519-1526.
64. Gamard CJ, Dbaibo GS, Liu B, Obeid LM, Hannun YA. Selective involvement of ceramide in cytokine-induced apoptosis: ceramide inhibits phorbol ester activation of nuclear factor kappaB. J Biol Chem 1997;272:16474-16481.
65. Gowda S, Yeang C, Wadgaonkar S, Anjum F, Grinkina N, Cutaia M, Jiang X-C, Wadgaonkar R. Sphingomyelin synthase 2 (SMS2) deficiency attenuates LPS-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2010;300:L430-L440.
66. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004;309:758-768.
67. Rosenfeldt HM, Amrani Y, Watterson KR, Murthy KS, Panettieri RA Jr., Spiegel S. Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells. FASEB J 2003;17:1789-1799.
68. Roviezzo F, Lorenzo A, Bucci M, Brancaleone V, Vellecco V, De Nardo M, Orlotti D, De Palma R, Rossi F, D'Agostino B, et al. Sphingosine-1-phosphate/ sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am J Respir Cell Mol Biol 2007; 36:757-762.
69. Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011;74:900-907.
70. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003;278:47281-47290.
71. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007;19:1754-1764.
72. Muller HC, Hocke AC, Hellwig K, Gutbier B, Peters H, Schnorock SM, Tschernig T, Schmiedl A, Hippenstiel S, N'Guessan PD, et al. The sphingosine-1-phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulm Pharmacol Ther 2011;24:377-385.
73. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349.
74. Billich A, Bornancin F, Devay P,Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003;278:47408-47415.
75. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004;26:585-587.
76. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 2002;520:97-101.
77. Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4- octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol Pharmacol 2006;70:41-50.
78. Bandhuvula P, Tam YY, Oskouian B, Saba JD. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 2005;280:33697-33700.
79. Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, Spiegel S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007;109:1077-1085.
80. Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, Mirzapoiazova T, Garcia JG, Natarajan V. FTY720 inhibits ceramide synthases and upregulates dihydrosphingosine-1-phosphate formation in human lung endothelial cells. J Biol Chem 2009;284: 5467-5477.
81. Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an acyl-CoA chain length-dependent manner. J Biol Chem 2009;284: 16090-16098.
82. Roberts KG, Smith AM, McDougal F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT1 cancers. Cancer Res 2010;70:5438-5447.
83. Wang L, Chiang ET, Simmons JT, Garcia JGN, Dudek SM. FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Eur Respir J 2011;38:78-88.
84. Singer II, Tian M, Wickham LA, Lin J, Matheravidathu SS, Forrest MJ, Mandala S, Quackenbush EJ. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol 2005;175:7151-7161.
85. Wei SH, Rosen H,MatheuMP, Sanna MG, Wang S-K, Jo E, Wong C-H, Parker I, CahalanMD. Sphingosine 1-phosphate Type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005;6:1228-1235.
86. Oo ML, Thangada S, Wu M-T, Liu CH, Macdonald TL, Lynch KR, Lin C-Y, Hla T. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007;282:9082-9089.
87. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-1564.
88. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355: 1124-1140.
89. Oo ML, Chang S-H, Thangada S, Wu M-T, Rezaul K, Blaho V, Hwang S-I, Han DK, Hla T. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 2011;121:2290-2300.
90. Krump-Konvalinkova V, Chwalla I, Siess W. FTY720 inhibits S1Pmediated endothelial healing: relationship to S1P1-receptor surface expression. Biochem Biophys Res Commun 2008;370:603-608.
91. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged S1P1 agonist exposure exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010;43: 662-673.
92. Hale JJ, Neway W, Mills SG, Hajdu R, Keohane CA, Rosenbach M, Milligan J, Shei G-J, Chrebt G, Bergstrom J, et al. Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. Bioorg Med Chem Lett 2004;14:3351-3355.
93. Foss FW, Clemens JJ, Davis MD, Snyder AH, Zigler MA, Lynch KR, Macdonald TL. Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors. Bioorg Med Chem Lett 2005;15:4470-4474.
94. Clemens JJ, Davis MD, Lynch KR, Macdonald TL. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. Bioorg Med Chem Lett 2005;15:3568-3572.
95. Zhu R, Snyder AH, Kharel Y, Schaffter L, Sun Q, Kennedy PC, Lynch KR, Macdonald TL. Asymmetric synthesis of conformationally constrained fingolimod analogues: discovery of an orally active sphingosine 1-phosphate receptor Type-1 agonist and receptor Type-3 antagonist. J Med Chem 2007;50:6428-6435.
96. Tarrason G, Auli M, Mustafa S, Dolgachev MT, Prats N, Dominguez M, Lopez R, Aguilar N, Calbet M, Pont M, et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and shortlasting peripheral blood lymphopenia in mice. Int Immunopharmacol 2011;11:1773-1779.
97. Lu X, Sun C, Valentine WJ, Shuyu E, Liu J, Tigyi G, Bittman R. Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720. J Org Chem 2009;74:3192-3195.
98. Wang L, Sammani S, Moreno-Vinasco L, Camp SM, Bittman R, Garcia JGN, Dudek SM. FTY720 S-phosphonate exhibits superior barrier promoting properties to S1P and FTY720 in vitro and in vivo. Am J Respir Crit Care Med 2011;183:A1954.
99. Tonelli F, Lim KG, Loveridge C, Long J, Piston SM, Tigyi G, Bittman R, Pyne S, Pyne NJ. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteosomal degradation in human pulmonary artery smooth muscle, breast cancer and androgenindependent prostate cancer. Cell Signal 2010;22:1536-1542.
100. Valentine WJ, Kiss GN, Liu J, Shuyu E, Gotoh M, Murakami-Murofushi K, Pham TC, Baker DL, Parrill AL, Lu X, et al. (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal 2010;22: 1543-1553.
101. Hla T. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat 2001;64:135-142.
102. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, et al. Edg-1, the G protein-coupled receptor for sphingosine 1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951-961.
103. Kono M, Allende ML, Proia RL. Sphingosine 1-phosphate regulation of mammalian development. Biochim Biophys Acta 2008;1781:435-441.
104. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu Y-P, Yamashita T, Proia RL. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 2004;279:29367-29373.
105. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 2007;27:1312-1318.
106. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, Wang T, Mathew B, Husain A, Moitra J, et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in murine lung. Am J Respir Cell Mol Biol 2010;43:394-402.
107. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 2007;117:2506-2516.
108. Sun X, Ma S-F, Wade MS, Moitra J, Garcia JGN. Two functional promoter variants of sphingosine-1-phosphate receptor 3 gene decrease human susceptibility to severe sepsis-associated acute lung injury. Am J Respir Cell Mol Biol 2011;183:A1345.
109. Ma S-F, Wade MS, Hysi P, Yates CR, Meduri GU, Zhao Y, Garcia JG, Natarajan V. Sphingosine kinase 1 gene polymorphisms are associated with acute lung injury in African and European Americans. Am J Respir Cell Mol Biol 2011;183:A3875.
110. Petrache I, Goya J, Rush NI, Van DeMark BS, Kamocki K, Petrusca DN, Twigg HL III, Garcia JGN, Ma S, Natarajan V, et al. Ceramide and sphingosine 1 phosphate (S1P) levels in patients with COPD. Am J Respir Cell Mol Biol 2010;181:A1539.